JP Morgan Chase
NTLA icon

JP Morgan Chase’s Intellia Therapeutics NTLA Stock Holding History

JP Morgan Chase’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,600
Closed -$79.4K – 7662
2025
Q3 		$79.4K Buy
+4,600
New +$56.7K ﹤0.01% 6035
2025
Q1 		– Sell
-20,400
Closed -$238K – 7612
2024
Q4 		$238K Buy
+20,400
New +$318K ﹤0.01% 5404

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase's NTLA Position: Q1 2026 in Review

JP Morgan Chase reduced its Intellia Therapeutics (NTLA) stake by 26% in Q1 2026, selling an estimated $2.49M and leaving 548,491 shares worth $6.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3095.

JP Morgan Chase first reported a position in NTLA in Q2 2016 and has held it in 36 quarters since. The position peaked at $145M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • JP Morgan Chase held 548,491 shares of Intellia Therapeutics worth $6.39M as of Q1 2026.
  • JP Morgan Chase sold 195,207 Intellia Therapeutics shares in Q1 2026, an estimated $2.49M.
  • Intellia Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3095 holding.
  • JP Morgan Chase first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 36 quarters since.
  • JP Morgan Chase's Intellia Therapeutics position peaked at $145M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.